NSE: BIOCON
BSE: BIOCON
Healthcare
Biocon Ltd.
Biocon Ltd. is a leading player in the Healthcare industry operating in India.
Current Price
₹1680.51
52W High/Low: ₹1983.00 / ₹1310.80
Market Cap
₹668822.98 Cr.
Stock P/E
38.19
Book Value
₹291.25
Dividend Yield
1.61%
ROCE
16.45%
ROE
27.01%
Debt
₹177903.82 Cr.
Cash
₹106742.29 Cr.
Intrinsic Value
₹1932.59
Industry P/E
34.37
Promoter Holding
47.53%
EPS (TTM)
₹44.00
Candlestick & Volume Chart
Pros
- Company has reduced debt significantly and is almost debt free.
- Company has been maintaining a healthy dividend payout of 1.61%.
- Solid return on equity (ROE) of 27.01% over the last 3 years.
- Robust ROCE at 16.45%, indicating excellent capital efficiency.
Cons
- The stock is trading at 5.77x book value, which may be on the higher side.
- Promoter holding has remained flat at 47.53% in recent quarters.
- Sales growth has been moderate compared to sector leaders in the past year.
Peer Comparison (Sector: Healthcare)
| Company | Price (₹) | Mkt Cap (₹ Cr.) | P/E | P/B | ROE (%) | ROCE (%) | Debt (₹ Cr.) | Div Yield (%) | Sales Growth (%) | Profit Growth (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbott India Ltd. | ₹1109.82 | 231408.33 | 59.58 | 3.67 | 27.65% | 21.16% | 1424.93 | 1.68% | 34.41% | 9.70% |
| Acutaas Chemicals Ltd. | ₹1643.75 | 948892.76 | 21.94 | 5.66 | 33.88% | 29.38% | 189546.56 | 3.88% | 14.46% | 19.01% |
| Ajanta Pharmaceuticals Ltd. | ₹1897.22 | 468277.04 | 71.79 | 2.50 | 43.10% | 48.99% | 162435.22 | 2.90% | 17.89% | 17.44% |
| Alkem Laboratories Ltd. | ₹3464.39 | 787795.47 | 48.86 | 5.14 | 17.75% | 39.41% | 266701.02 | 3.36% | 20.54% | 29.58% |
| Anthem Biosciences Ltd. | ₹2501.16 | 376325.09 | 34.33 | 11.67 | 43.60% | 28.22% | 97169.98 | 3.55% | 14.34% | 36.48% |
| Apollo Hospitals Enterprise Ltd. | ₹101.00 | 916274.17 | 14.83 | 7.02 | 8.03% | 34.35% | 52019.80 | 2.06% | 6.95% | 27.14% |
| Aster DM Quality Care Ltd. | ₹3535.71 | 1226326.85 | 46.03 | 2.23 | 26.76% | 42.01% | 254081.82 | 0.97% | 25.95% | 16.43% |
| Aurobindo Pharma Ltd. | ₹2348.15 | 1080408.41 | 73.99 | 4.85 | 11.54% | 42.49% | 99197.61 | 1.64% | 9.49% | 20.75% |
| Biocon Ltd. Current | ₹1680.51 | 668822.98 | 38.19 | 5.77 | 27.01% | 16.45% | 177903.82 | 1.61% | 22.15% | 31.50% |
| Blue Jet Healthcare Ltd. | ₹4396.60 | 1022905.06 | 27.21 | 6.87 | 14.29% | 17.72% | 294201.37 | 0.24% | 22.23% | 26.23% |
| Caplin Point Laboratories Ltd. | ₹3938.15 | 603952.60 | 28.22 | 4.41 | 22.88% | 45.60% | 73792.91 | 3.42% | 32.16% | 17.61% |
| Cipla Ltd. | ₹4112.38 | 197272.17 | 59.71 | 5.50 | 43.76% | 51.70% | 50598.16 | 4.08% | 8.83% | 13.64% |
| Cohance Lifesciences Ltd. | ₹1216.82 | 1436180.46 | 63.82 | 4.81 | 19.36% | 39.17% | 46763.50 | 3.30% | 7.15% | 25.05% |
| Concord Biotech Ltd. | ₹3841.95 | 140594.83 | 57.24 | 2.70 | 33.50% | 51.86% | 28124.13 | 0.28% | 17.17% | 33.28% |
| Divi's Laboratories Ltd. | ₹161.74 | 75736.04 | 40.68 | 5.78 | 37.37% | 25.60% | 4022.59 | 3.12% | 32.40% | 24.52% |
| Dr. Lal Path Labs Ltd. | ₹430.51 | 75577.34 | 45.14 | 10.68 | 30.07% | 50.07% | 5720.96 | 0.70% | 12.23% | 21.89% |
| Dr. Reddy's Laboratories Ltd. | ₹4492.04 | 321981.21 | 11.76 | 5.35 | 23.95% | 49.17% | 105620.44 | 2.97% | 28.19% | 9.21% |
| Emcure Pharmaceuticals Ltd. | ₹897.68 | 288336.80 | 33.89 | 8.47 | 31.21% | 19.61% | 10154.19 | 2.79% | 15.86% | 23.28% |
| Eris Lifesciences Ltd. | ₹2887.91 | 452323.31 | 54.39 | 6.82 | 25.05% | 10.89% | 61388.73 | 1.69% | 23.78% | 15.07% |
| Fortis Healthcare Ltd. | ₹4420.22 | 1406992.35 | 12.49 | 4.41 | 26.52% | 24.59% | 120595.99 | 2.48% | 15.79% | 10.55% |
| Gland Pharma Ltd. | ₹3453.30 | 360995.74 | 34.21 | 4.56 | 15.54% | 14.29% | 18264.92 | 2.11% | 25.65% | 15.64% |
| Glaxosmithkline Pharmaceuticals Ltd. | ₹188.88 | 809050.23 | 59.79 | 8.55 | 44.62% | 52.34% | 213252.05 | 3.37% | 34.81% | 41.27% |
| Glenmark Pharmaceuticals Ltd. | ₹4157.80 | 551758.16 | 52.02 | 2.11 | 46.71% | 46.13% | 135060.16 | 2.87% | 16.58% | 30.57% |
| Global Health Ltd. | ₹3420.38 | 736585.86 | 33.69 | 5.68 | 18.80% | 20.62% | 135330.21 | 2.03% | 26.04% | 35.02% |
| Granules India Ltd. | ₹2853.05 | 465379.65 | 19.70 | 8.19 | 17.34% | 17.57% | 50441.84 | 0.43% | 5.37% | 40.36% |
| Indegene Ltd. | ₹3952.70 | 873495.73 | 10.55 | 11.27 | 12.11% | 37.44% | 189460.05 | 1.64% | 13.36% | 40.86% |
| Ipca Laboratories Ltd. | ₹3634.62 | 1179580.67 | 66.30 | 11.36 | 9.25% | 38.82% | 65963.54 | 2.92% | 10.13% | 11.86% |
| Jubilant Pharmova Ltd. | ₹1897.22 | 468277.04 | 71.79 | 2.50 | 43.10% | 48.99% | 162435.22 | 2.90% | 17.89% | 17.44% |
| Krishna Institute of Medical Sciences Ltd. | ₹883.84 | 1450285.19 | 31.81 | 9.86 | 18.71% | 29.62% | 436900.00 | 2.05% | 32.35% | 38.17% |
| Laurus Labs Ltd. | ₹1288.95 | 1198829.92 | 31.37 | 4.79 | 36.26% | 23.90% | 337951.55 | 3.53% | 33.38% | 19.65% |
| Lupin Ltd. | ₹2787.98 | 681342.04 | 48.83 | 10.82 | 43.84% | 19.22% | 50477.62 | 3.66% | 11.02% | 10.13% |
| Mankind Pharma Ltd. | ₹1643.75 | 948892.76 | 21.94 | 5.66 | 33.88% | 29.38% | 189546.56 | 3.88% | 14.46% | 19.01% |
| Max Healthcare Institute Ltd. | ₹2106.01 | 29617.11 | 19.09 | 11.89 | 29.94% | 37.99% | 8901.76 | 3.06% | 25.71% | 22.63% |
| NATCO Pharma Ltd. | ₹3433.91 | 1014059.74 | 37.92 | 8.12 | 25.25% | 54.28% | 333702.27 | 4.35% | 5.59% | 37.92% |
| Narayana Hrudayalaya Ltd. | ₹3715.94 | 1343023.32 | 20.59 | 4.48 | 27.13% | 17.33% | 43134.87 | 3.38% | 27.32% | 19.32% |
| Neuland Laboratories Ltd. | ₹1221.82 | 535880.63 | 62.22 | 2.01 | 23.92% | 46.82% | 16036.88 | 0.39% | 6.23% | 26.81% |
| Onesource Specialty Pharma Ltd. | ₹3117.63 | 195799.70 | 37.62 | 4.31 | 46.71% | 39.44% | 43365.69 | 3.10% | 16.20% | 28.37% |
| Pfizer Ltd. | ₹1260.05 | 822607.78 | 49.39 | 3.69 | 19.16% | 17.42% | 98957.68 | 2.07% | 30.32% | 39.70% |
| Piramal Pharma Ltd. | ₹2850.73 | 966167.87 | 53.17 | 6.27 | 26.37% | 31.27% | 257918.97 | 1.47% | 27.79% | 21.52% |
| Poly Medicure Ltd. | ₹1255.17 | 74040.89 | 34.78 | 2.97 | 20.90% | 50.62% | 22833.77 | 3.52% | 29.42% | 40.68% |
| Rainbow Childrens Medicare Ltd. | ₹3960.20 | 160323.30 | 62.27 | 10.21 | 39.65% | 32.03% | 30964.77 | 2.93% | 16.68% | 9.14% |
| Sai Life Sciences Ltd. | ₹3186.14 | 1374623.70 | 22.08 | 2.98 | 13.37% | 36.19% | 269461.27 | 1.53% | 25.78% | 30.44% |
| Sun Pharmaceutical Industries Ltd. | ₹1854.99 | 208936.29 | 48.94 | 10.94 | 27.28% | 53.45% | 57050.02 | 3.92% | 8.22% | 15.55% |
| Syngene International Ltd. | ₹3284.21 | 1488404.64 | 22.95 | 6.16 | 36.72% | 16.24% | 277538.42 | 4.45% | 14.44% | 30.29% |
| Torrent Pharmaceuticals Ltd. | ₹2495.30 | 1308643.80 | 21.12 | 5.56 | 37.49% | 14.89% | 399555.89 | 2.57% | 28.92% | 32.28% |
| Vijaya Diagnostic Centre Ltd. | ₹1568.62 | 985313.07 | 57.75 | 4.76 | 20.43% | 51.22% | 67070.84 | 3.19% | 21.44% | 34.01% |
| Wockhardt Ltd. | ₹3433.91 | 1014059.74 | 37.92 | 8.12 | 25.25% | 54.28% | 333702.27 | 4.35% | 5.59% | 37.92% |
| Zydus Lifesciences Ltd. | ₹273.07 | 233787.00 | 73.10 | 3.89 | 11.11% | 14.65% | 43092.49 | 1.66% | 16.81% | 32.61% |
Quarterly Financial Trends
| Quarter | Sales (₹ Cr.) | Expenses (₹ Cr.) | Operating Profit (₹ Cr.) | OPM (%) | Other Income (₹ Cr.) | Interest (₹ Cr.) | Depreciation (₹ Cr.) | Profit Before Tax (₹ Cr.) | Tax (%) | Net Profit (₹ Cr.) | EPS (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 FY25 | 33441.15 | 0.00 | 8025.88 | 24.22% | 668.82 | 668.82 | 1337.65 | 5350.58 | 25.00% | 4012.94 | 11.00 |
| Q2 FY25 | 33441.15 | 0.00 | 8025.88 | 19.22% | 668.82 | 668.82 | 1337.65 | 5350.58 | 25.00% | 4012.94 | 11.00 |
| Q3 FY25 | 33441.15 | 0.00 | 8025.88 | 14.34% | 668.82 | 668.82 | 1337.65 | 5350.58 | 25.00% | 4012.94 | 11.00 |
| Q4 FY25 | 33441.15 | 0.00 | 8025.88 | 13.19% | 668.82 | 668.82 | 1337.65 | 5350.58 | 25.00% | 4012.94 | 11.00 |
Yearly Profit & Loss Statements
| Year | Sales (₹ Cr.) | Expenses (₹ Cr.) | Operating Profit (₹ Cr.) | OPM (%) | Other Income (₹ Cr.) | Interest (₹ Cr.) | Depreciation (₹ Cr.) | Profit Before Tax (₹ Cr.) | Tax (%) | Net Profit (₹ Cr.) | EPS (₹) | Div Payout (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No profit & loss statement available. | ||||||||||||
Balance Sheet Summary
| Year | Share Capital (₹ Cr.) | Reserves (₹ Cr.) | Borrowings (₹ Cr.) | Other Liabilities (₹ Cr.) | Total Liabilities (₹ Cr.) | Fixed Assets (₹ Cr.) | CWIP (₹ Cr.) | Investments (₹ Cr.) | Other Assets (₹ Cr.) | Total Assets (₹ Cr.) |
|---|---|---|---|---|---|---|---|---|---|---|
| No balance sheets available. | ||||||||||
Statement of Cash Flows
| Year | Cash from Operating Activity (₹ Cr.) | Cash from Investing Activity (₹ Cr.) | Cash from Financing Activity (₹ Cr.) | Net Cash Flow (₹ Cr.) |
|---|---|---|---|---|
| No cash flow statements available. | ||||
Key Financial Ratios
| Year | ROCE (%) | ROE (%) | Debtor Days | Inventory Turnover | Interest Coverage Ratio |
|---|---|---|---|---|---|
| No ratio data available. | |||||
Filings & Investor Updates
No recent documents available.
Management Credibility Scorecard
5-Year Historical Guidance vs. Actual Achievement Track Record
Overall Score: 86/100
Reliability %
86.00%
Achieved / Total
7 / 9
Delayed Commitments
2
Avg Delay (Months)
0.00 mo
5-Year Forecast History
| FY Guidance | Metric & Statement | Target vs Actual | Source & Page | Status | Local PDF |
|---|---|---|---|---|---|
| No management forecasts synced for this company. | |||||
Local Filing Document Archive
G:\My Drive\NETPROFIT\FOLIUX\screener\result\BIOCON\No local archived documents found.
Exchange Announcements & News
Audited Financial Results For The Quarter Ended June 30, 2026
July 10, 2026The board of directors approved the quarterly financial reports, showing a sales growth of 22.15% YoY.
Media Release - Performance Highlights And Expansion Strategy
July 08, 2026Annual general meeting outlines capital allocation, targeting green initiatives and tech development to boost ROCE.
FOLIUX AI Score
60/100
Fair Hold
Detailed Breakdown
Buy Score
77%
Valuation Score
65%
Growth Score
91%
Financial Health
84%
Technical Strength
82%